Mulher, História, Imprensa e Constituinte: uma análise do jornal O Estado do Paraná

The study about the role media play in society is frequent. Thisresearch studied National Constitution Assembly frought Estado do Paraná (newspaper) discussing press behavior in this period. A letter of Brazilian women to the constitution makers written in 1988 was analyzed. This document was made by women a social movement of outstanding importance and power in this period. It was researched how the text built women as social and historical agents in front of the Constitution the articulations constructed around subjects of the time the subjects with feminist tried to interact and the hegemony intended. There is also a tentative to actualize an regionalize this discussion.O estudo sobre o papel que os meios de comunicação de massadesempenham na sociedade é recorrente. A pesquisa que abordou a Assembléia Nacional Constituinte no jornal O Estado do Paraná investigou o comportamento da imprensa. A Carta da Mulher Brasileira aos Constituintes de 1988 é documento redigido pelas mulheres, movimento e sujeito social de crucial importância e força no período. Pesquisou-se como o texto constrói a mulher como agente histórico e social frente à Constituinte, as articulações tecidas em torno dos temas inerentes ao período, os sujeitos com os quais o movimento feminista buscou interagir e a hegemonia tencionada. Há uma tentativa de contemporanizar e regionalizar esta discussão

Eficácia do tratamento empírico da prostatite crônica na redução do PSA em pacientes com PSA 4NG/ML

01

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

El Pueblo : diario republicano de Valencia: El Pueblo : diario republicano de Valencia - Año XXXI Número 11442 - 1924 enero 29 (29/01/1924)

Numeración errónea en el original, se ha corregido

MEIS1 intronic risk haplotype associated with restless legs syndrome affects its mRNA and protein expression levels

Restless legs syndrome (RLS) is a common neurological disorder characterized by an irresistible urge to move the legs at night, which is often accompanied by unpleasant sensations. A recent genomewide association study identified an association between RLS and intronic markers from the MEIS1 gene. Comparative genomic analysis indicates that MEIS1 is the only gene encompassed in this evolutionarily conserved chromosomal segment, i.e. a conservation synteny block, from mammals to fish. We carried out a series of experiments to delineate the role of MEIS1 in RLS pathogenesis and the underlying genetic mechanism. We sequenced all 13 MEIS1 exons and their splice junctions in 285 RLS probands with confirmed clinical diagnosis and did not identify any causative coding or exon–intron junction mutations. We found no evidence of structural variation or disease-associated haplotype differential splicing. However, sequencing of conserved regions of MEIS1 introns 8 and 9 identified a novel single nucleotide polymorphism (C13B_2) significantly associated with RLS (allelic association, P = 1.81E−07). We detected a significant decrease in MEIS1 mRNA expression by quantitative real-time polymerase chain reaction in lymphoblastoid cell lines (LCLs) and brain tissues from RLS patients homozygous for the intronic RLS risk haplotype, compared with those homozygous for the non-risk haplotype. Finally, we found significantly decreased MEIS1 protein levels in the same batch of LCLs and brain tissues from the homozygous carriers of the risk haplotype, compared with the homozygous non-carriers. Therefore, these data suggest that reduced expression of the MEIS1 gene, possibly through intronic cis-regulatory element(s), predisposes to RLS